The following listing of claims will replace all prior versions and listings of claims in the application.

## IN THE CLAIMS

1. (currently amended) A compound of Formula I:

$$S$$
 $O-CH_2C(R_1)(R_2)CH_2-N(R_3)(R_4)$ 

Formula I

a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-8</sub> alkoxy;

R2 is H-or C1-6 alkyl;

R₃ is (CH₂), Q, CH₂CH(OH)Q, CH(CH₃)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phonyl, or furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2 methylenedioxyphenyl, cyclohexenyl, 1H pyrazolo[4,3 c]pyridyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2; and

R<sub>4</sub> H or C<sub>1-8</sub> alkyl; or.

R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1.4 dioxa-8-aze-spire[4.5]decanyl, piperazinyl, morphelinyl, piperadinyl, pyrrelidinyl, azecanyl, 1.2.3.4 tetrahydroisequinelinyl, 1,2,3.4 tetrahydro-β-carbelinyl, 4,5,6.7 tetrahydrothienyll3,2-e]pyridyl, er-8-aza-bicyclo[3.2.1.]ectane, each of which may be meno- or independently di-substituted with halo, C<sub>1-6</sub> alkyl, C<sub>1-8</sub> alkexy, C(O)phonyl, OH, CN, O-phonyl or (CH<sub>2</sub>)<sub>m</sub>Z<sub>1</sub>

Z is benzisexazolyl, indazolyl, benzisethiazolyl, benzethienyl, pyrimidinyl, pyridyl, 1,2 methylenedioxyphonyl, or phenyl, and

Z, CH(OH)phonyl or O-phonyl are optionally substituted with one or two moleties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, trifluoromethyl, S(O)<sub>2</sub>NH<sub>2</sub>, or syano, and

-2-

## m-is-0 or 1;

## provided that when R<sub>1</sub> is OH, R<sub>2</sub> is H:

- (1)  $R_4$  is H, and  $R_3$  is  $(CH_2)_nQ$ , where n is 1 or 2, then Q cannot be indelyl or phenyl; or
- (2) R<sub>3</sub> and R<sub>4</sub> form piperazinyl substituted with (CH<sub>2</sub>)<sub>m</sub>Z, when m is 1, then Z cannot be phenyl.
- (currently amended) A compound according to claim 1 wherein
   Q is thienyl <del>or pyridyl;</del>
   or R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form piperidinyl.
- 3. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[thienophen-2-ylmethyl)-amino-propan-2-ol.
- 4. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-3-ylmethyl)-amino]-3-(3-thieno[2,3-\darkgreen]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 5. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-2-ylmethyl)-amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 6. (withdrawn) The compound according to claim 2 which is (2S)-1-(2-thlenylmethylamino)-2-methyl-3-[3-thleno[2,3-\darkalpha]isoxazol-3-yl-phenoxy]propan-2-ol.
- 7. (withdrawn) The compound according to claim 2 which is (2S)-1-[4-(3-chlorophenoxy)-1-piperidinyl]-2-methyl-3-[3-thieno[2,3-a]isoxazol-3-yl-phenoxy]propan-2-ol.
- 8. (withdrawn) The compound according to claim 2 which is (2S)-1-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-2-methyl-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
- 9. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-4-ylmethyl)-amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 10. (withdrawn) The compound according to claim 2 which is (2R)-1-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 11. (withdrawn) The compound according to claim 2 which is (2S)-1-(3-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
- 12. (withdrawn) The compound according to claim 2 which is (2S)-2-methyl-1-[(pyridin-3-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.

- 13. (withdrawn) The compound according to claim 2 which is (2S)-2-methyl-1-[(pyridin-2-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 14. (withdrawn) The compound according to claim 2 which is (4-fluorophenyl)-(1-{2(R)-hydroxy-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propyl}-piperidin-4-yl)-methanone.
- 15. (withdrawn) The compound according to claim 2 which is 1-(1-{2(R)-hydroxy-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propyl}-piperidin-4-yl)-1,3-dihydrobenzimidazol-2-one.
- (withdrawn) A compound according to claim 2 wherein
   R<sub>1</sub> is OH;

R<sub>2</sub> is H;

 $R_3$  is  $(CH_2)_n Q$ ; or

 $R_3$  and  $R_4$  together with the nitrogen atom to which  $R_9$  and  $R_4$  are attached form piperidinyl; and

n is 1.

- 17. (withdrawn) A compound according to claim 16 wherein Q is thlenyl.
- 18. (withdrawn) The compound according to claim 17 which is (2R)-1-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)-amino]-propan-2-ol.
- 19. (withdrawn) The compound of claim 17 which is (2R)-1-(4-thieno[2,3-a]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)-amino]-propan-2-ol.
- 20. (withdrawn) The compound of claim 17 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)amino]propan-2-ol.
- 21. (withdrawn) The compound of clalm 17 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)amino]propan-2-ol.
- 22. (withdrawn) A compound according to claim 16 wherein Q is pyridyl.
- 23. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-4-yl)methylamino]-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
- 24. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-2-ylmethyl)-amino]-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)-propan-2-ol.
- 25. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-3-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 26. (withdrawn) A compound according to claim 16 wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form piperidinyl.
- 27. (withdrawn) The compound according to claim 26 which is 4-(4-chlorophenyl)-1- {(R)2-hydroxy-3-[3-(thieno[2,3-d]isoxazol-3-yl)phenoxy]propyl}plperidin-4-ol.

- 28. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 29. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-chlorobenzo[d]isoxazol-3-yl)plperidin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 30. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-fluorobenzo[d]isothiazol-3-yl)-piperdin-1-yl]-3-(thleno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 31. (withdrawn) The compound of claim 26 which is (2R)-1-(4-benzylpiperidin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 32. (withdrawn)The compound of claim 26 which is (2R)-1-piperidin-1-yl-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)-propan-2-ol.
- 33. (withdrawn) A compound according to claim 1 wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form piperazinyl.
- 34. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-chlorophenyl)piperazIn-1-yl]-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 35. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-methoxyphenyl)-piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 36. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-fluorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-\d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 37. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-fluorophenyi)piperzain-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 38. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 39. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(3-chlorophenyl)piperazin-1-yl]-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 40. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-methoxyphenyl)piperazin-1-yl]-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)-propan-2-ol.
- 41. (withdrawn) The compound of claim 33 which is (2R)-1-(4-phenylpiperazin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 42. (withdrawn) The compound of claim 33 which is 2-{4-[(R)-2-hydroxy-3-(3-thleno[2,3-d]lsoxazol-3-yl-phenoxy)-propyl]piperazin-1-yl}benzonitrile.
- 43. (withdrawn) The compound of claim 33 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[4-(2-trifluoromethylphenyl)-piperazin-1-yl]propan-2-ol.

- (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-44. methoxyphenyl)piperazin-1-yl]-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- (withdrawn) The compound of claim 33 which is 2-{4-[(R)-2-hydroxy-3-(4-thieno[2,3-45. d]isoxazol-3-yl-phenoxy)propyl]-piperazin-1-yl}benzonitrile.
- 46. (withdrawn) The compound of claim 33 which is (2S)-1-[4-(2methoxyphenyl)piperazin-1-yl]-2-methyl-3-[3-thieno[2,3-d]isoxazol-3-ylphenoxy]propan-2-ol.
- 47. (withdrawn) The compound of claim 33 which is (2S)-1-[4-(2-cyanophenyl)-1piperazinyl]-2-methyl-3-[3-thleno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
- 48. (withdrawn) The compound of claim 33 which is (2R)-1-(4-pyrimidin-2-yl-piperazin-1yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 49. (withdrawn) The compound of claim 33 which is (2R)-1-(4-pyridin-2-yl-piperazin-1yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- (withdrawn) The compound of claim 33 which is (2R)-1-(4-benzo[1,3]dioxol-5-50. ylmethyl-piperazin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 51. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(6-fluoro-1H-indazol-3-yl)piperazin-1-yl]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 52. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(5-methoxy-1H-indazol-3yl)-piperazin-1-yl]-3-(3-thieno[2,3-a]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 53. (withdrawn) The compound of claim 33 which is (2R)-1-(4-benzo[d]isothiazol-3-ylpiperazin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 54. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(6-fluorobenzo[b]thiophen-3-yl)plperazin-1-yl]-3-(3-thieno[2,3-q]isoxazol-3-yl-phenoxy)-propan-2-ol.
- (withdrawn) The compound of claim 33 which is 3-{(R)-4-[2-hydroxy-3(3-thieno[2,3-55. d]isoxazol-3-yl)phenoxy]propyl]-piperazin-1-yl}-benzo[d]isoxazol-6-ol.
- (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-methoxyphenyl)-3-56. methylplperazin-1-yl]-3-[3-(thieno[2,3-d]isoxazol-3-yl)phenoxy]propan-2-ol.
- 57. (withdrawn) The compound of claim 33 which is (2R)-1-[3-(1-methyl-1H-thleno[3,2c]pyrazol-3-yl)-phenoxy-3-(4-phenyl-piperazin-1-yl)-propan-2-ol.
- 58. (withdrawn) The compound of claim 33 which is (2R)-1-[3-(1-methyl-1H-thieno[3,2c]pyrazol-3-yl)-phenoxy-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol.
- 59. (withdrawn) A compound according to claim 1 wherein Q is phenyl.
- (withdrawn) The compound of claim 59 which is (2R)-1-(4-chlorobenzylamino)-2-60. methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

- 61. (withdrawn) The compound of claim 59 which is (2R)-1-[(N-benzyl-N-methyl)amino]-3-[2-thieno[2,3-a]isoxazol-3-yl)phenoxy]-2-propanol.
- 62. (withdrawn) The compound of claim 59 which is (2S)-(+)-1-benzylamino-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 63. (withdrawn) The compound of claim 59 which is (2R)-(-)-1-benzylamino-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 64. (withdrawn) The compound of claim 59 which is (2R)-1-(benzylmethylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 65. (withdrawn) The compound of claim 59 which is (2R)-1-(4-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 66. (withdrawn) The compound of claim 59 which is (2R)-1-(4-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 67. (withdrawn) The compound of claim 59 which is (2R)-1-(2-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 68. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-3-(4-trifluoromethylbenzylamino)-propan-2-ol.
- 69. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-[1(R)-phenylethylamino]-3-(3-thieno[2,3-d]isoxazol]-3-yl-phenoxy)-propan-2-ol.
- 70. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-[1(S)-phenylethylamino]-3-(3-thleno[2,3-d]isoxazol]-3-yl-phenoxy)-propan-2-ol.
- 71. (withdrawn) The compound of claim 59 which is (2R)-1-(2-hydroxy-2-phenylethylamino)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 72. (withdrawn) The compound of claim 59 which is (2R)-benzyl-[2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propyl]-methylamine hydrochloride.
- 73. (withdrawn) The compound of claim 59 which is (2R)-benzyl-[2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propyl]-amine.
- 74. (withdrawn)The compound of claim 59 which is (2S)-1-(4-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 75. (withdrawn) The compound of claim 59 which is (2S)-1-(2-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol,
- 76. (withdrawn) The compound of claim 59 which is (2S)-1-(3-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)propan-2-ol.
- 77. (withdrawn) The compound of claim 59 which is (2\$)-1-(4-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)propan-2-ol.

- 78. (withdrawn) The compound of claim 59 which is (2S)-1-(2-chlorobenzylamino)-2-methyl-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 79. (withdrawn) The compound of claim 59 which is (2S)-1-(3,4-dichlorobenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 80. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-[1(R)-phenylethylamino]-3-(3-thieno[2,3-d]isoxazol]-3-yl-phenoxy)-propan-2-ol,
- 81. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-[1(S)-phenylethylamino]-3-(3-thieno[2,3-d]isoxazol]-3-yl-phenoxy)-propan-2-ol.
- 82. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-(4-methylbenzylamino)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 83. (withdrawn) The compound of claim 59 which is (2S)-1-(4-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 84. (withdrawn) The compound of claim 59 which is (2S)-1-(2-methoxybenzylamino)-2-methyl-3-(3-thleno[2,3-a]isoxazol-3-yl-phenoxy)propan-2-ol.
- 85. (withdrawn) The compound of claim 59 which is (2S)-1-(benzylmethylamino)-2-methyl-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
- 86. (withdrawn) The compound of claim 59 which is (2S)-1-(3,4-difluorobenzylamino)-2-methyl-3-[3-(thieno[2,3-d]isoxazol-3-yl)phenoxy]propan-2-ol.
- 87. (withdrawn) The compound of claim 59 which is (2R)-1-(2-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 88. (original) A compound according to claim 1 wherein Q is furanyl.
- 89. (withdrawn) The compound of claim 88 which Is (2R)-1-[(furan-2-ylmethyl)-amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 90. (withdrawn) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)amino]-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 91. (withdrawn) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)-amino]-3-(4-thleno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 92. (withdrawn) The compound of claim 88 which is (2S)-1-[(furan-2-ylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 93. (original) A compound according to claim 1 wherein R<sub>3</sub> is indanyl.
- 94. (withdrawn) The compound of claim 93 which is (2R)-1-(Indan-1-ylamino)-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)-propan-2-ol.
- 95. (withdrawn) The compound of claim 93 which is (2R)-1-(indan-2-ylamino)-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 96. (withdrawn) A compound according to claim 1 wherein Q is naphthyl.

- 97. (withdrawn) The compound of claim 96 which is (2R)-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-d]lsoxazol-3-yl-phenoxy)propan-2-ol.
- 98. (withdrawn) The compound of claim 96 which is (2R)-2-methyl-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 99. (withdrawn) The compound of claim 96 which is (2R)-1-[(naphthalen-1-ylmethyl)-amino]-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 100. (withdrawn) The compound of claim 96 which is (2S)-2-methyl-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 101. (withdrawn) A compound according to claim 1 wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,2,3,4-tetrahydroisoquinolinyl.
- 102. (withdrawn) The compound of claim 101 which is is (±)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[2-(thleno[2,3-d]isoxazol-3-yl)phenoxy]-2-propanol.
- 103. (withdrawn) The compound of claim 101 which is (2R)-1-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]-3-[3-(thleno[2,3-d]isoxazol-3-yl)phenoxy]propan-2-ol.
- 104. (withdrawn) The compound of claim 101 which is (2R)-1-(3,4-dihydro-1H-Isoquinolin-2-yl)-3-[2-(thieno[2,3-d]isoxazol-3-yl)phenoxyl-2-propanol.
- 105. (withdrawn) The compound of claim 101 which is (2R)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[3-(1-methyl-1H-thleno[3,2-c]pyrazol-3-yl)-phenoxy]-propan-2-ol.
- 106. (withdrawn) A compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,2,3,4-tetrahydro-β-carbolinyl.
- 107. (withdrawn) The compound of claim 106 which is (2R)-1-(1,2,3,4-tetrahydro-β-carbolin-2-yl)-3-[3-thieno[2,3-α]isoxazol-3-yl)phenoxy]propan-2-ol.
- 108. (withdrawn) A compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl.
- 109. (withdrawn) The compound of claim 108 which is (2R)-1-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 110. (withdrawn) The compound of clalm 108 which is (2R)-1-(6,7-dihydro-4H-thieno[3,2-c]pyrldin-5-yl)-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 111. (withdrawn) A compound according to claim 1, wherein R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 8-aza-bicyclo[3.2.1.]octane.
- 112. (withdrawn) The compound of claim 111 which is (2R)-1-(3-benzo[d]isoxazol-3-yl-8-azabicyclo[3.2.1]oct-8-yl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.
- 113. (original) A compound according to claim 1, wherein R<sub>3</sub> is adamantyl.

- 114. (withdrawn) The compound of claim 113 which is (2R)-1-(adamantan-1-ylamino)-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 115. (withdrawn) A compound according to claim 1, wherein Q is cyclohexyl.
- 116. (withdrawn) compound of claim 115 which is (2R)-1-(cyclohexylmethyl-amino)-3-(3-thleno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.
- 117. (withdrawn) A compound according to claim 1, wherein Q is benzimidazolyl.
- 118. (withdrawn) The compound of claim 117 which is (2R)-1-[(1H-benzimidazol-2-ylmethyl)amino]-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.
- 119. (original) A compound according to claim 1, wherein R<sub>3</sub> is 1,2,3,4-tetrahydronaphthyl.
- 120. (withdrawn) The compound of claim 119 which is (2R)-1-(1,2,3,4-tetrahydronaphthalen-1-ylamino)-3-[3-thieno[2,3-d]isoxazol-3-yl)phenoxy]propan-2-ol.
- 121. (withdrawn) A compound of formula

wherein X is  $N(CH_3)$  or O; and  $R_1$  is H or  $C_{1-8}$ alkyl.

122. (withdrawn) A compound of formula

wherein X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is H or C<sub>1-8</sub>alkyl; and

R<sub>2</sub> is CH<sub>3</sub>, F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene.

- 123. (withdrawn) A method for antagonizing the effects of dopamine at the D<sub>4</sub> receptor comprising administering a compound according to claim 1 to a patient in need thereof.
- 124. (original) A composition comprising a compound according to claim 1 in admixture with an inert carrier.

- 125. (original) The composition according to claim 124 wherein said inert carrier is a pharmaceutical carrier.
- 126. (withdrawn) A method of treating psychoses comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 127. (withdrawn) A method of treating Attention Deficit Hyperactivity Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 128. (withdrawn) A method of treating Obsessive-Compulsive Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 129. (withdrawn) A method of treating Substance Abuse comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 130. (withdrawn) A method of treating Substance Dependence comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 131. (withdrawn) A method of treating Parkinson's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 132. (withdrawn) A method of treating Parkinsonism comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 133. (withdrawn) A method of treating Tardive Dyskinesia comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 134. (withdrawn) A method of treating Gilles de la Tourette Syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 135. (withdrawn) A method of treating Conduct Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 136. (withdrawn) A method of treating Oppositional Defiant Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
- 137. (withdrawn) A method of making a compound of formula I

a pharmaceutically acceptable sait or stereoisomer thereof,

wherein

X is N(CH<sub>3</sub>) or O;

 $R_1$  is OH or  $C_{1-6}$  alkoxy;

R<sub>2</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q, CH<sub>2</sub>CH(OH)Q, CH(CH<sub>3</sub>)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2;

R<sub>4</sub> is H or C<sub>1-8</sub> alkyl; or

 $R_3$  and  $R_4$ , together with the nitrogen atom to which  $R_3$  and  $R_4$  are attached, form 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-substituted with halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, C(O)phenyl, OH, CN, O-phenyl or  $(CH_2)_m Z$ ,

- Z is benzisoxazolyl, indazolyl, benzisothlazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and
- Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, trifluoromethyl, S(O)<sub>2</sub>NH<sub>2</sub>, or cyano, and

m is 0 or 1;

comprising the step of coupling a reagent of formula II

wherein X and  $R_2$  are as defined in formula I; with a reagent of formula III

wherein R<sub>3</sub> and R<sub>4</sub> are as defined in formula I:

138. (withdrawn) A method of making a compound of formula I

$$S$$
 $O-CH_2C(R_1)(R_2)CH_2-N(R_3)(R_4)$ 

a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-6</sub> alkoxy;

R<sub>2</sub> is H or C<sub>1-6</sub> alkyl;

 $R_3$  is  $(CH_2)_n$  Q,  $CH_2CH(OH)Q$ ,  $CH(CH_3)Q$ , 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2:

R<sub>4</sub> is H or C<sub>1-6</sub> alkyl; or

R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,4-dloxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinollnyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-substituted with halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH<sub>2</sub>)<sub>m</sub>Z,

- Z is benzisoxazolyl, indazolyl, benzisothlazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and
- Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moleties independently selected from halo, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkoxy, hydroxy, trifluoromethyl, S(O)<sub>2</sub>NH<sub>2</sub>, or cyano, and

m is 0 or 1;

comprising the step of coupling a compound of formula II

wherein X and R<sub>2</sub> are as defined in formula I; and R<sub>5</sub> is CH<sub>3</sub>, CF<sub>3</sub>, F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene:

with a reagent of formula III

wherein R<sub>3</sub> and R<sub>4</sub> are as defined in formula I; to provide the compound of formula I.

139. (withdrawn) A method of making a compound of formula I

$$O-CH_2C(R_1)(R_2)CH_2-N(R_3)(R_4)$$

a pharmaceutically acceptable salt or stereoisomer thereof. wherein

X is N(CH<sub>3</sub>) or O;

R<sub>1</sub> is OH or C<sub>1-6</sub> alkoxy;

R<sub>2</sub> is H or C<sub>1-6</sub> alkyi;

R<sub>3</sub> is (CH<sub>2</sub>)<sub>n</sub> Q, CH<sub>2</sub>CH(OH)Q, CH(CH<sub>3</sub>)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

- Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl, and
- Q is optionally substituted with one or two moieties independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, hydroxy, S(O)<sub>2</sub>NH<sub>2</sub>, trifluoromethyl, or cyano, and

n is 1 or 2;

R<sub>4</sub> is H or C<sub>1-8</sub> alkyl; or

R<sub>9</sub> and R<sub>4</sub>, together with the nitrogen atom to which R<sub>3</sub> and R<sub>4</sub> are attached, form 1,4dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydrolsoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-substituted with halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH<sub>2</sub>)<sub>m</sub>Z,

- Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedloxyphenyl, or phenyl, and
- Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkoxy, hydroxy, trifluoromethyl, S(O)2NH2, or cyano, and

m is 0 or 1;

comprising the step of coupling a reagent of formula II.

wherein X is as defined in formula I; with a reagent of formula III

wherein  $R_2$ ,  $R_3$ , and  $R_4$  are as defined in formula I; to provide the compound of formula I.